LRRK2 and Parkinson disease: Our results demonstrate that inhibition of LRRK2 kinase activity can normalize GCase substrate accumulation and downstream deficits in lysosomal function and highlight the therapeutic potential of LRRK2 inhibitors to correct lysosomal dysfunction observed in PD.